Milan/Fidenza (Italy), 30 November 2017 - Funds advised by Triton ("Triton") have successfully completed the acquisition of Bormioli Rocco’s pharma business (“Bormioli Pharma”), a leading pharma primary packaging manufacturer from Vision Capital. Terms of the acquisition were not disclosed.
"We want to support the management and employees of the Bormioli Pharma business by investing in and supporting the growth and development of the company. We will contribute our strategic insights from the industry and region. We look forward to working together with the management team and the Board of Directors in building a stronger company", said Peder Prahl, Director of the General Partner for the Triton funds.
"Bormioli Pharma, as a market leader, has been continuously building its current presence over the last years. This transaction is an important milestone, enabling the company to continue with its strategic efforts", said Riccardo Garrè, Executive Chairman of Bormioli Rocco.
“Bormioli Pharma is a great company in an interesting industry segment with strong fundamentals and we are looking forward to supporting its further growth and development in the coming years”, added Fabrizio Gualdi, Investment Advisory Professional and Advisor to the Triton Funds.
About Bormioli Pharma
Established in 1825, Bormioli Rocco’s pharma business is a leading Italian pharma primary packaging manufacturer. Bormioli Rocco Pharma has 5 manufacturing plants and sells its products to more than 90 countries worldwide. Bormioli Rocco Pharma employs over 900 people and has an annual turnover of € 217 million.
About Triton Partners
Founded in 1997 and owned by its partners, Triton Partners is a leading European mid-market sector-specialist investor. Triton Partners focuses on investing in businesses that provide mission critical goods and services in its three core sectors of Business Services, Industrial Tech, and Healthcare.
Triton Partners has over 150 investment professionals and value creation experts across eleven offices and invests through three complementary “All Weather” strategies: Mid-Market Private Equity, Smaller Mid-Cap Private Equity, and Opportunistic Credit.